Therapeutics: FMS-like tyrosine kinase 3 ligand (FLT3LG); BRAF; programmed cell death 1 ligand 1 (PD-L1; B7-H1; CD274)

Cancer

INDICATION: Melanoma

Mouse studies suggest FLT3LG plus poly I:C could help treat BRAF-mutant melanoma.

Read the full 133 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE